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VARIABILITY OF FEES IN THE FIELD OF PHYSICAL THERAPY IN THE
AUSTRIAN CONTRACT PHYSICIANS’ AND INSTITUTES’ SECTOR
Wilbacher I, Scholler C, Weisser A, Endel G
Main Association of Austrian Social Security Institutions, Vienna, Vienna, Austria
OBJECTIVES: Contracts with physicians or institutes that perform health care ser-
vices can provide price advantages due to competition. The sickness funds of the 
Austrian Social Security signed different contracts concerning physical therapy with
physicians or institutes. Claims data, respectively rendered fees suggest a possible 
savings potential in the fee for service system without reducing the scope of the pro-
cedures or the frequencies. We analyzed the variety of fees in the ﬁ eld of physical
therapy including contracted physicians and institutes. This shows variability among
the total amount of reimbursement in the Austrian outpatient sector consisting of 
contracted physicians, institutes, and outpatient clinics of hospitals and ambulatories. 
The outpatient sector is supplied with services by contracted physicians. Approxi-
mately 30% of the Austrian outpatient sector cannot be displayed since no data is
available from outpatient clinics of hospitals. METHODS: Price differences for the 
same or similar procedures performed by different contracted physicians or institutes
are evaluated. Different ﬁ nancial impacts (e.g. focusing on average or lowest value)
are simulated. Values were rounded to two decimal points, however, calculated by 15 
decimal points. The fee equals the division of turnover and frequency. RESULTS:
Services in physical therapy were brought into account 13.412.401 times in the year 
2006. Calculating all frequencies with the lowest paid fee (turnover/frequency) for 
each service would lead to a lower ﬁ nancial effort of 43% compared to the current
turnover. Calculating all frequencies with the highest fee for service would lead to a
higher effort of 82% compared to the current turnover. CONCLUSIONS: A current 
savings potential of 82%, contrasting the current fee with the most expensive one, 
indicates a well established fee negotiation. However, a savings potential of 43% is
worth being considered for further evaluation and, if necessary, the adjustment of fees
is advisable.
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EVALUATING COST DIFFERENCES AMONG OPERATIONAL TEAMS 
SUPPORTING THE INDIANA HEALTH INFORMATION EXCHANGE
Bansal M1, Grannis S2, Kansky J3, Morrison W1
1Indiana University, Indianapolis, IN, USA, 2The Regenstrief Institute, Inc, Indianapolis, IN, USA, 
3Indiana Health Information Exchange, Indianapolis, IN, USA
OBJECTIVES: Health Information Exchange (HIE) is emerging in health care markets 
across the US at an accelerating rate. However, one of the greatest barriers to building
and sustaining HIE organizations is a clear understanding of the costs. We analyzed
personnel costs for managing data connections in the Indiana health information 
exchange (IHIE). IHIE’s data infrastructure is managed by project management (PM),
system engineering (SE) and data mapping (DM) teams. Each team is involved in dif-
ferent tasks but to connect a hospital they coordinate overlapping tasks. To gage
ongoing maintenance expenses we evaluated the cost differences among the teams.
METHODS: We interviewed team members to gather level of effort data for imple-
menting and maintaining IHIE data interfaces. Personnel costs were calculated by 
multiplying the level of effort by staff salaries. Annual personnel costs were determined
by the total interfaces implemented per year. We projected personnel costs for years 
2004–2008 by using a constant level of effort and an increasing number of hospitals 
and annual salary. We used one-way ANOVA to detect differences among the average 
cost per team for managing interfaces. RESULTS: The three teams (PM, SE, and DM) 
exhibited different average costs. The DM team produced the largest average cost and 
level of effort followed by SE and then PM. Using ANOVA and with critical value of 
0.10, the cost differences were statistically signiﬁ cant (p  0.055). CONCLUSIONS:
Since the cost differences are signiﬁ cant, it suggests the differences are not due to
chance but are largely due to level of effort variances. The level of effort differs because 
each team performs different tasks with varying degrees of complexity. Additional, 
difﬁ cult to quantify factors include size of hospitals, proﬁ ciency of hospital mainte-
nance staff and adequate frequency of interactions; they appear in the average costs 
indirectly.
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PREDICTING HEALTH SERVICE UTILIZATION WITH THE PCS 
AND MCS OF THE SF-36
Chen T
Zhejiang University, Hangzhou, China
OBJECTIVES: We aim to predict outpatient consultation and inpatient consultation 
with two summary scores of the SF-36, physical component summary (PCS) and
mental component summary (MCS). METHODS: A retrospective cross-sectional 
design was carried out among primary care patients in mainland China. Health-related 
quality of life (HRQOL) was measured by two summary score of the SF-36, PCS and
MCS, Either the electronic or the paper version of validated Chinese SF-36 was used 
in the survey. Outpatient consultation was calculated by the monthly outpatient con-
sultation rate and inpatient consultation was calculated by the annual hospitalization
rate. Binary logistic regression for consultation and inpatient consultation was adopted
in the analyses. A total of 733 valid subjects were eventually recruited in this study. 
RESULTS: For the monthly outpatient consultation rate, the odds ratios (OR) and 
95% conﬁ dence interval (CI) were 0.919 (0.891, 0.947) for PCS and 0.995 (0.970,
1.021) for MCS. For the annual hospitalization rate, OR and 95% CI were 0.907
(0.884, 0.930) for PCS and 0.951 (0.927, 0.975) for MCS. CONCLUSIONS: PCS of 
the SF-36 can predict both outpatient consultation and inpatient consultation, whereas 
MCS of the SF-36 can predict inpatient consultation among primary care patients in 
mainland China.
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LEGISLATIVE ASPECTS OF HEALTH TECHNOLOGY ASSESSMENT
IN SLOVAKIA
Tomek D1, Bielik J2
1Slovak Society for Pharmacoeconomics, Bratislava, Slovak Republic, 2Trencin University, 
Trencin, Slovak Republic
OBJECTIVES: Pharmaceutical expenditures in Slovakia accounts for a higher share 
of total health expenditures than it does in any other OECD country. Although health
spending is well below the OECD average when considered as a share of GDP, Slova-
kias pharmaceutical expenditures accounts Thirty-two percent of total health care 
budget. The accessibility and availability of medicines, even the most innovative 
products is good. METHODS: We have analysed the relevant legislation and ofﬁ cial 
reimbursement decisions and commentaries, published by the MoH in 2008 that are 
accessible either via internet or directly per request in MoH. RESULTS: Mandatory 
HTA (pharmacoeconomy) is incorporated in all relevant legislation. The main drug
reimbursement body – Categorisation committee of the MoH – received a special 
advisory body “Working group for pharmacoeconomics and outcomes research”. The 
working group consists of experts who evaluate all reimbursement applications for 
new drugs and prepare an assessment of the HTA part of the application. Recently,
MoH refused reimbursement in several cases, including new indications in innovative
oncology drugs. CONCLUSIONS: The focus of the MoH drug policy is on more 
rational spendings, especially on reference pricing and HTA. Where the reference
pricing is effective from April 1, 2009, estimated savings for 2009 are up to 1 bil €
($1.34 billion), or 10% of the total drug bill. Referencing and the savings is a not 
repeatable issue, so the mandatory HTA is effective in practice (that means, not just 
legislation but also implementation) from January 1, 2009. There are ﬁ rst results of 
these new procedures, where the real impact of the HTA in the decision processes is
demonstrated.
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THE CHANGING DYNAMICS IN HEALTH CARE FUNDING
Sparrowhawk K, Long M, Watch J
PriceSpective, London, UK
OBJECTIVES: Traditionally, the US can be broadly deﬁ ned as having three sources
of funding (private insurance, out-of-pocket funding and public funding through
Medicare/Medicaid). This funding triangle can lead to varying degrees of inequality 
in the health care system. Meanwhile, European markets generally fund health care
either through statutory health insurance schemes or by the government with very 
little being paid for directly by the patient. However, as governments consider how to 
meet their growing health care needs in a global recession, many will look towards a 
combination of cost reduction and new funding sources. This scramble to fund health 
care services will open markets to ideas once thought off-limits: just as the US starts 
moving towards universal care, some European markets, such as the UK, are consider-
ing the idea of supplemental, private provision of health care. METHODS: Review 
of US states that now require health insurance, literature regarding the impact of 
Medicare Part D and policy papers regarding potential federal level changes to the 
provision of health care. Review of changes to the EU5 (France, Germany, Italy, Spain
and the UK), including changes in the size of the private insurance market, the amount
paid through co-payments and policy announcements regarding greater reliance on 
out of pocket/private funding. Review of the amount of generic drug versus branded 
pharmaceuticals spend in each market. RESULTS: Despite growing utilization of 
generic drugs, health care systems are still struggling to fund the rising cost of health 
care. While the US system is moving towards a greater reliance on government funded 
health care, European markets are realizing necessity of additional funding sources. 
CONCLUSIONS: In order to stretch budgets to meet growing health care needs, the
6 major markets are moving to a more diverse funding matrix for health care and, 
along the way, will more closely resemble one another.
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INCREMENTAL SICK LEAVE COSTS AND LOST TIME AMONG
EMPLOYEES WITH PSYCHIATRIC AND MEDICAL CONDITIONS
Brook RA1, Kleinman NL2, Melkonian AK3, Smeeding J4
1The JeSTARx Group, Newfoundland, NJ, USA, 2HCMS Group, Paso Robles, CA, USA, 3The 
HCMS Group, Cheyenne, WY, USA, 4The JeSTARx Group, Dallas, TX, USA
OBJECTIVES: To compare the incremental costs and absences due to sick leave (SL) 
among employees with bipolar disorder (BPD), other mental disorders (OMD), 
chronic constipation (CC), functional dyspepsia (FD), gastroesophageal reﬂ ux disease
(GERD), gout, and insomnia. METHODS: A 2001–2007 US employee database was 
used to identify subjects with BPD, OMD, CC, FD, GERD, gout, and insomnia. All 
studies used two-part regression models to control for differences between employees
with the condition and control groups (employees without the condition). SL costs 
were based on payments made to the employee (adjusted to 2007 US dollars) and 
absences were based on reported hours missed. Controls (by study) used the average 
index date of the subjects with the condition. Incremental costs and absences were 
deﬁ ned as adjusted differences between the condition cohort and controls and consid-
ered signiﬁ cant at P a 0.05. RESULTS: Numbers of employees with SL eligibility for 
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the condition/controls (employees without condition) were: BPD 239/85,420; OMD 
5508/76,372; CC 920/143,287; FD 918/143,138; GERD 6172/133,466; gout
600/123,461; and insomnia 7951/134,094. All incremental SL cost differences
were signiﬁ cant (P  0.05). From highest to lowest, the incremental annual SL costs 
(condition-control) were: gout  $359(172.5% higher than controls), insomnia
 $208(162.1%), OMD  $175(142.4%), GERD  $169(141.1%), CC 
$127(133.8%), FD  $120(128.8%), BPD  $94(119.7%). From highest to lowest, 
the incremental annual absence days were: gout  2.8(178.3% of control), OMD 
2.3(186.9%), BPD  1.9(157.0%), insomnia  1.6(175.4%), GERD  1.3(141.5%),
FD  0.8(126.7%), and CC  0.7(130.5%). CONCLUSIONS: Employees with insom-
nia, FD, GERD, gout, CC, BPD, and OMD incur more absences and costs than
employees without these conditions, suggesting that management of these conditions 
should focus on both the workplace and health care settings. Because individual sala-
ries were used to calculate the costs for each condition, the differences in the ordering
of the incremental days and payments may be attributable to job-related differences
between the diseases. Gout had the highest incremental costs and days of any of the 
studied conditions.
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DOES IMPROVING QUALITY OF CARE SAVE MONEY? ANALYSIS OF
HEALTH CARE EFFECTIVENESS DATA AND INFORMATION SET (HEDIS)
MEASURES
Broder MS1, Ory C1, Yermilov I2, Ko C2, Maggard MA2, Keeler EB3
1Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA, 2UCLA Center for 
Surgical Outcomes and Quality, Los Angeles, CA, USA, 3RAND Health, Santa Monica, CA, 
USA
OBJECTIVES: To determine whether improving quality of care saves money we
examined costs and beneﬁ ts of increasing compliance with the 2006 Healthcare
Effectiveness Data and Information Set (HEDIS) measures. METHODS: We systemati-
cally reviewed English-language scientiﬁ c literature (1998–2008) for US or Western
European cost effectiveness analyses published as original articles that compared
HEDIS-compliance to non-compliance and reported cost and beneﬁ ts. We abstracted 
costs, effectiveness, and incremental cost effectiveness ratios (ICER). Using US Census 
data, we calculated the total annual cost and beneﬁ t associated with moving from
2006 HEDIS rates to 95% compliance. RESULTS: We screened 1641 articles, reviewed 
222, and accepted 18 (relating to 19 of 25 measures). Greater compliance with 6 
measures reduced costs. Increasing compliance with the remaining 13 measures
increased costs but improved health; ICERs varied from $180/quality-adjusted-life-
year (QALY) (initiation of alcohol/drug treatment) to $39,805/QALY (breast cancer
screening). The number of people required to reach 95% compliance varied from 0
for beta-blocker use after MI (2006 compliance 96.6%) to 39 million for ﬂ u shots 
(2006 compliance 44.5%%). The most costly measure was comprehensive diabetes 
care ($7 billion/year) and the least costly were increasing childhood immunizations 
and reducing inappropriate imaging studies for back pain (each saving almost $400 
million/year). 95% compliance on all measures would cost $13.2 billion annually, save
$1 billion (net $12.2 billion), and add 7 million QALYs for a mean overall cost effec-
tiveness of under $2000/QALY. CONCLUSIONS: Improving quality using a nation-
ally accepted list of quality measures would increase, not reduce, costs. A published
study estimated that recent medical advances have improved health at a cost of $30–
$85,000/QALY; in comparison, improving compliance with HEDIS measures may be
an attractive investment. If more HEDIS measures examined overuse (e.g. of treat-
ments with inadequate evidence of effectiveness), improving compliance with the entire
set might reduce costs.
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BUDGETARY POLICIES AND AVAILABLE ACTIONS: A GENERALISATION
OF DECISION RULES FOR ALLOCATION AND RESEARCH DECISIONS
McKenna C1, Chalabi Z2, Epstein D1, Claxton K1
1University of York, York, UK, 2London School of Hygiene and Tropical Medicine, London, UK
OBJECTIVES: Uncertain decisions made using a cost-effectiveness threshold applied 
to each decision problem separately fail to identify the true opportunity costs of displac-
ing other unrelated programmes. We show that the allocation problem can be charac-
terised to provide a more general and comprehensive approach to informing adoption 
and research decisions. METHODS: A stochastic mathematical programming approach
is used to solve the allocation problem. The formulation allows the characterisation of 
actual budgetary policies, including a strict budgetary rule where deﬁ cits are not pos-
sible and constraints must always be met. The opportunity costs (health forgone due 
to curtailing some programmes and treatments) of violating the budget constraint are 
incorporated directly. In addition, the value of acquiring new evidence to inform the
allocation problem in light of its current uncertainty is considered simultaneously and 
consistently. RESULTS: The allocation and research decision problem depends on a 
number of considerations: 1) size of overall budget; 2) budgetary policy in place; 3)
information that is revealed and its timing; 4) subsequent actions available to decision
makers; and 5) costs of effectively monitoring ex-ante plans. Standard decision rules 
in cost-effectiveness analysis are only optimal under very special circumstances, which 
require budget constraints to be soft in addition to assumptions of perfect divisibility,
constant returns and all costs and beneﬁ ts occurring within the budgetary period.
However, if the budget constraint is hard then technologies will need to be more cost-
effective (an incremental cost-effectiveness ratio substantially below the threshold)
before the decision maker should take the risk of an ex-ante decision to adopt them. 
CONCLUSIONS: Standard decision rules and measures of value are proxies for an 
uncertain and complex process. There are no simple ex-ante decision rules in most
common circumstances and the value of information cannot be established for one 
programme independently of the rest of the allocation problem.
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EVALUATING DIFFERENCES IN DRUG REIMBURSEMENT BETWEEN
MAIL-ORDER AND COMMUNITY PHARMACY
Visaria J1, Seoane-Vazquez E1, Rodriguez-Monguio R2, Schwartzbaum J1, Szeinbach SL1
1Ohio State University, Columbus, OH, USA, 2University of Massachusetts, Amherst, Amherst, 
MA, USA
OBJECTIVES: Reimbursement for the same drug may differ with respect to channel
of distribution. The objective of this study was to assess differences in reimbursement 
per unit of product dispensed and to compare pharmaceutical expenditures between 
mail-order and community pharmacy. METHODS: Pharmacy claims from a retire-
ment system for the period 2000–2005 were used in the analysis. Differences in reim-
bursement per unit of product dispensed and expenditures were estimated using a 
basket of drug items (i.e. unique combinations of drug products, formulations, 
strength, and generic status) dispensed in both channels. Rebates were not included 
in the analysis. Differences were assessed using bootstrapped 90% percentile and 
hybrid conﬁ dence intervals. RESULTS: The comparison basket contained 1,964 items 
and 4,001,243 claims. In 2005, 52.07% of the items had higher reimbursement per 
unit in community pharmacy, 35.80% had higher reimbursement in mail-order phar-
macy and 13.31% had equal reimbursement. In 2005, estimated pharmaceutical 
expenditures of the comparison basket were $558.93 million using mail-order phar-
macy prices and $623.66 million using community pharmacy prices. This difference 
was attributed to higher reimbursement of ingredient cost, administrative fees and 
dispensing fees in community pharmacy. The difference in estimated pharmaceutical
expenditures of the comparison basket between community and mail-order pharmacy 
decreased from 12.8% in 2000 to 10.4% in 2005. Estimated pharmaceutical expen-
ditures in both channels increased from 2000–2005. The difference in total expendi-
tures, ingredient cost, dispensing, administration and other fees between channels 
decreased during the study period. CONCLUSIONS: Nearly one-half of all compara-
ble items had higher reimbursement per unit in community pharmacy than mail-order 
pharmacy. Overall expenditures were signiﬁ cantly lower in mail-order pharmacy.
Differences in pharmaceutical expenditures between community and mail-order phar-
macy were explained by differences in acquisition costs and fees. Decision makers 
should carefully evaluate pharmaceutical reimbursement including discounts, fees and
rebates when deciding the most efﬁ cient dispensing channel.
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TRENDS IN DESIGN CHARACTERISTICS OF BRIEF SUMMARY 
ON PRINT ADS OF PRESCRIPTION DRUGS: A FIVE YEAR STUDY
Dwibedi N1, Sansgiry SS2
1University of Houston, HOUSTON, TX, USA, 2University of Houston, Houston, TX, USA
OBJECTIVES: To evaluate and compare trends in design characteristics of brief-
summary formats of prescription drug print ads. METHODS: The source for these 
ads include a consumer magazine – National Geographic (NG) and three medical
journals – Annals of Internal Medicine (AIM), The Journal of the American Medical 
Association (JAMA) and The New England Journal of Medicine (NEJM). Each source
was visually reviewed by research assistants to record information from brief sum-
maries on ads from issues dated January 1, 2000 through December 31, 2004. The
design characteristics evaluated were text font size, font consistency, presence of 
bullets, highlights, tables, graphs, format type (e.g.: question/answer format), warning 
box, spacing between lines, and number of columns used to present the material. Font
size was measured using the Compugraphic scale. Data were coded and analyzed using
SAS 9.1. Descriptive statistics and comparisons using chi-square tests were per-
formed to evaluate differences by year and source at a priori signiﬁ cance level of 0.05.
RESULTS: A total of 7266 printed ads for 240 products manufactured by 90 phar-
maceutical companies were evaluated from NG (95), AIM (1372), JAMA (1787), and 
NEJM (4012) respectively. There were signiﬁ cant differences (p  0.05) in most design
characteristics by year (2000–2004), namely font consistency, presence of bullets,
highlights, tables, graphs, and warning box. These differences were also statistically
signiﬁ cant (p  0.05) across sources (magazine/journals). The question/answer format
and presence of a warning box was mostly seen in ads obtained from the magazine. 
The mean (SD) font size of the text on these ads was small (5.7 o 1.1) and consistent 
throughout these ads by year and source. CONCLUSIONS: Prescription drug print 
ads have changed over the years and are different based on the readership source.
Further improvement in standardizing the format and increasing the text font may 
help the intended readers of these ads.
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COMPRISON OF NOTIFIABLE DISEASES SURVELLIANCE 
WEBSITES OF FOUR COUNTRIES
Agarwal SJ, Sansgiry SS
University of Houston, Houston, TX, USA
OBJECTIVES: Globalization necessitates better co-ordination among countries to
monitor disease outbreaks. The spread of SARS in 2003 highlights this need. Hence,
this study compared the notiﬁ able diseases surveillance websites of four countries. 
METHODS: Twenty-ﬁ ve countries were identiﬁ ed from literature that had published 
Human Development Index 0.9 and Quality-of-Life index 7. Four countries from 
this list were selected, namely, United States (US), Canada, Australia, and New 
Zealand. Fourteen European Union member countries were excluded, as they have a 
process to harmonize and consolidate their disease surveillance networks in place by 
